In a welcome move, Axsome Therapeutics (AXSM) saw its Relative Strength Rating improve from 69 to 72 on Thursday.
17 hours ago

Pallas Capital Advisors LLC lifted its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 7.1% during the second quarter,...
14 hours ago

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the...
1 day ago

Mark L. Jacobson, Chief Operating Officer of Axsome Therapeutics Inc (NASDAQ:AXSM), sold a total of 45,783 shares of common stock on...
1 day ago

Axsome Therapeutics presents six innovative neuroscience studies at Psych Congress 2025, focusing on CNS disorders like depression and...
1 day ago

If you're trying to figure out whether to buy, hold, or simply watch Axsome Therapeutics, you're in good company.
3 days ago

Axsome Therapeutics presents six clinical studies across major depressive disorder, Alzheimer's agitation, narcolepsy, and sleep apnea at...
1 day ago

Strs Ohio acquired a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the 1st quarter, according to its most recent...
17 hours ago

Investing.com - Piper Sandler has reiterated its Overweight rating on Axsome Therapeutics (NASDAQ:AXSM), a $5.7 billion market cap biotech...
1 day ago

Axsome Therapeutics (NASDAQ:AXSM) Chief Executive Officer Herriot Tabuteau sold a total of 62,880 shares of common stock between September...
1 day ago